Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
| + | * [[Media:QIBA PET Amyloid Profile.pdf| QIBA PET Amyloid Profile 2017-04-28]] (BC Vote to Release for Public Comment Form: ) | ||
| + | :*[[Media: QIBA PET Amyloid Profile Edits.xlsx|QIBA PET Amyloid Profile Edits and Open Issues]] | ||
* [[Media:QIBADWIProfilev1.45_20170427_v5_accepted.pdf| DWI Profile 2017-04-27]] (Public Comment Form: https://goo.gl/fkL6rB) | * [[Media:QIBADWIProfilev1.45_20170427_v5_accepted.pdf| DWI Profile 2017-04-27]] (Public Comment Form: https://goo.gl/fkL6rB) | ||
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | * [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | ||
Revision as of 15:47, 1 May 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
- QIBA PET Amyloid Profile 2017-04-28 (BC Vote to Release for Public Comment Form: )
- DWI Profile 2017-04-27 (Public Comment Form: https://goo.gl/fkL6rB)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
- QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)